A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1613 participants.

Also called NCT05872620

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,613 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05872620
Other papers using this trial's data
  • Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Lancet (London, England), 2026-12-20 DOI, PubMed 41275875

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05872620. Randomized; double masking; primary purpose treatment. Start 2023-06-05 (actual); primary completion 2025-08-08 (actual). Results posted on 2026-09-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Acronym
ATTAIN-2
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05872620
Content hash
6bafff09c6466d6c7b36f447438a5f6fa42c052895140e7e5c3f016ba3547d12